Key result
Aspirin resistance in obese patients reduces its efficacy for cardiovascular disease prevention, which may be attenuated through weight loss, alternative dosing regimens, and different formulations.
Why the study?
With the global rise of obesity, there is an imperative need to address aspirin resistance and find preventive therapies that adequately target atherosclerotic cardiovascular disease risk in this population.
Does obesity contribute to aspirin resistance and reduced efficacy in preventing cardiovascular disease?
Does obesity contribute to aspirin resistance and reduced efficacy in preventing cardiovascular disease?
Obesity contributes to aspirin resistance, highlighting the need for alternative dosing or formulations to adequately address ASCVD risk in this population.
Obesity may heighten aspirin resistance in prevention; leaves open tailored dosing or alternatives for obese patients.
Aspirin resistance (AR) commonly refers to the concept of reduced aspirin efficacy in preventing cardiovascular disease and platelet inhibition. Obesity increases the risk of heart disease three- to four-fold and has been associated with AR. Aspirin is used as a tool for both primary and secondary prevention, but recent studies suggest that its lack of efficacy for primary prevention is partly attributable to obesity. Several mechanisms have been described that contribute to AR in obese patients using pharmacokinetics and pharmacodynamics. AR may be attenuated through weight loss, alternative dosing regimens, and different drug formulations. With the global rise of obesity, it is imperative to find preventive therapies that adequately address atherosclerotic cardiovascular disease (ASCVD) risk in this population.
No takes yet. Share an insight, caveat, or question.
Ardeshna et al. (2019) conducted a review in Aspirin resistance in obesity. Aspirin was evaluated. Aspirin resistance in obese patients reduces its efficacy for cardiovascular disease prevention, which may be attenuated through weight loss, alternative dosing regimens, and different formulations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: